Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase
  • Animals
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage*
  • Antibody-Dependent Cell Cytotoxicity / drug effects*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Cell Line
  • Cell Line, Tumor
  • Drug Interactions
  • Humans
  • Killer Cells, Natural / drug effects*
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / metabolism
  • Lymphoma, B-Cell / drug therapy
  • Lymphoma, B-Cell / immunology
  • Mice
  • Protein Kinase Inhibitors / pharmacology
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrazoles / administration & dosage*
  • Pyrazoles / adverse effects*
  • Pyrimidines / administration & dosage*
  • Pyrimidines / adverse effects*
  • Rituximab

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Rituximab
  • Protein-Tyrosine Kinases
  • Agammaglobulinaemia Tyrosine Kinase